Dickkopf Related Protein-1 (Dkk-1) ELISA
Dickkopf-1 is an inhibitor of the Wnt/beta-catenin signal pathway, which has been implicated in the development of several types of cancers. It has been suggested that Dkk-1 could be a useful serum biomarker for screening against a variety of cancers, and that anti-Dkk-1 antibodies are potential tools for diagnosis and treatment of cancer. Dkk-1 is particularly expressed in lung cancer cells; an increasing concentration of Dkk-1 is significantly associated with tumour progression and decreased survival in patients with lung cancer. Determination of both Dkk-1 and NSE levels can significantly increase sensitivity of small cell lung cancer diagnostics where a severe lack of an optimal diagnostic marker is widely reported. The use of Dkk-1 and cytokeratin 19 fragment also increased the sensitivity of detection of non-small cell lung cancer. High serum levels of Dkk-1 were found in patients with cancers of the oesophagus, pancreas, stomach, liver, bile duct, breast and cervix. Dkk-1 level increases early in prostate cancer development and in a stepwise manner in multistep hepatocarcinogenesis. A recently published study indicated that increased serum level and protein expression of Dkk-1 can be a marker and predictor of poor prognosis in patients with gastric cancer. A new DKK-1 ELISA kit has enhanced Biovendor’s cancer diagnostic test portfolio. The superior assay sensitivity is characterised by a LOD of 10 pg/mL.
Supplier: BioVendor Research and Diagnostic Products
Website:
